25 related articles for article (PubMed ID: 1748396)
21. Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea.
Lazzarino M; Morra E; Brusamolino E; Alessandrino EP; Orlandi E; Pagnucco G; Castagnola C; Bernasconi P; Merante S; Bonfichi M
Hematol Oncol; 1991; 9(6):299-305. PubMed ID: 1748396
[TBL] [Abstract][Full Text] [Related]
22. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
Bauduer F; Delmer A; Blanc MC; Delmas-Marsalet B; Cadiou M; Rio B; Marie JP; Zittoun R
Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
[TBL] [Abstract][Full Text] [Related]
23. Extramedullary blast crisis in chronic myeloid leukemia.
Specchia G; Palumbo G; Pastore D; Mininni D; Mestice A; Liso V
Leuk Res; 1996; 20(11-12):905-8. PubMed ID: 9009247
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
25. [Cause of death, survival, and prognostic factors in a series of 98 patients with chronic myeloid leukemia].
Jonte F; Fernández-Fuertes F; Cecchini C; Luño E; Ordóñez A; Fernández C; Suárez P; Lausín A; Fernández J
Sangre (Barc); 1992 Oct; 37(5):351-4. PubMed ID: 1293774
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
